Skip to main content
2024 Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Paulo Paixao, PhD

Assistant Professor (Also a European Medicines Agency National Expert)
Univ of Lisbon

Paulo Paixão is an Assistant Professor in Pharmacokinetics and Biopharmaceutics at the Faculty of Pharmacy, University of Lisbon, a position he has held since 2012. Throughout his academic career, he has contributed to the field through his participation in 14 research projects, including one as Principal Investigator. Dr. Paixão has organized 11 national and international conferences and has a publication record with 39 papers, 3 book chapters, and 3 proceedings. He boasts an h-index of 16 and has delivered 23 oral communications and 26 poster presentations. His work has been recognized with 4 scientific awards.
In academia, Dr. Paixão has supervised 7 PhD theses (6 of which are ongoing) and 14 master’s theses, reflecting his commitment to mentoring the next generation of scientists. His research primarily focuses on pharmacokinetics and Therapeutic Drug Monitoring. He has made contributions to drug development tools, particularly in the optimization and application of Quantitative Structure-Activity Relationship (QSAR) models and data integration procedures with Physiologically-Based Pharmacokinetic (PBPK) models. His work on oral drug absorption modeling and simulation has influenced bioavailability and bioequivalence regulatory science, including the establishment of pharmacokinetic metrics for bioequivalence of modified release formulations and the evaluation of similarity metrics for dissolution profiles. More recent research interests include investigating the physiology of the gastrointestinal tract and its impact on clinical variability in oral drug products.
In addition to his academic role, Dr. Paixão has served as a Clinical Pharmacology assessor at INFARMED, the Portuguese Regulatory Agency, since 2003. He has also been a member of the Pharmacokinetics Working Party (PKWP) and is currently a member of the Methodological Working Party (MWP) at the European Medicines Agency (EMA). In his regulatory work, he has been involved in the assessment of bioequivalence and clinical pharmacokinetics across Centralized, Decentralized, Mutual Recognition, and National Procedures. Moreover, he has participated in Scientific Advice Procedures at both the national and European levels.

Disclosure information not submitted.

Presentation(s):